USP30 and neurodegenerative disease: This promising avenue offers new hope for restoring mitochondrial function in neurodegenerative diseases marked by mitochondrial dysfunction and opens the door to further preclinical and clinical investigations, positioning USP30 inhibitors as exciting candidates for disease‐modifying treatments.